Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2026-01-04 @ 9:52 PM
Study NCT ID:
NCT05472467
Status:
UNKNOWN
Last Update Posted:
2022-07-25
First Post:
2022-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
Sponsor:
Sichuan Cancer Hospital and Research Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCCHEC-01-2021-091
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None